Nuvoco Vistas Corporation Fund Raise of ₹700 Cr

Nuvoco Vistas Corporation Earnings Call Transcript: Key Takeaways

Nuvoco delivered resilient volume growth despite severe monsoon headwinds and significant fuel cost spikes.

Nuvoco Vistas Corporation Investor Presentation: Key Takeaways

Nuvoco reports 9% YoY volume growth and 11% EBITDA growth in Q2 FY27. Strategy focuses on premiumization (45% trade mix) and capacity expansion to 35 MMTPA via Vadraj acquisition.

Nuvoco Vistas Corporation Results Update

Nuvoco Vistas reported Q2 FY27 financial results with Rs 2,790 Cr revenue and Rs 411 Cr EBITDA, while commissioning 2 MMTPA grinding capacity in Surat.

cement grinding capacity

2.0 MMTPA

Nuvoco Vistas Corporation Q2 FY27 Results: Net Profit ₹64.8 Cr, Up 78.0% YoY

Nuvoco Vistas Corporation Ltd reported revenue from operations of ₹2,790 Cr (+13.5% YoY) and net profit of ₹64.8 Cr (+78.0% YoY) for Q2 FY27.

Key figure

Net profit ₹64.8 Cr · +78.0% YoY

Nuvoco Vistas Corporation Other Announcement

Nuvoco Vistas Corporation Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with regulatory reporting requirements.

Nuvoco Vistas Corporation Merger & Restructuring

Nuvoco Vistas' Board approved the voluntary liquidation of its wholly-owned subsidiary, Algebra Endeavour Private Limited, to simplify the Group's structure.

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.